Regeneron this week today announced two new collaborations with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), to develop new treatments combating infectious diseases. The first collaboration is focused on discovery, research, development and manufacturing of a portfolio of antibodies targeting up to 10 pathogens that pose significant risk to public health, starting with Influenza virus. The second collaboration (announced by HHS on September 29) builds on a prior agreement to develop and manufacture Regeneron’s potential therapy for Ebola virus. This investigational treatment has completed a Phase 1 clinical study and received Orphan Drug Designation from the U.S. Food and Drug Administration.
“We look forward to expanding upon our prior work with BARDA, as we continue our joint efforts to address serious public health threats,” said George Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron. “Our decades of investment in foundational technology platforms have resulted in a cutting-edge approach to drug discovery and development, and we’re proud to apply this technology against serious infectious threats such as Influenza virus and Ebola virus.”